Atossa Therapeutics Issues Letter to Shareholders
Atossa Therapeutics(ATOS) Newsfilter·2024-01-09 13:30SEATTLE, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, today announces the issuance of the following Letter to Shareholders from Steven Quay, M.D., Ph.D., the Company's President and Chief Executive Officer: To our valued shareholders: 2023 marked another year of significant progress for Atossa. There are now four Phase ...